We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer.
- Authors
Smith, Joshua D.; Ludwig, Megan L.; Bhangale, Apurva D.; Brummel, Collin; Swiecicki, Paul L.; Worden, Francis P.; Chinn, Steven B.; Stucken, Chaz L.; Rosko, Andrew J.; Prince, Mark E. P.; Malloy, Kelly M.; Casper, Keith A.; Bradford, Carol R.; Chepeha, Douglas B.; Shah, Jennifer; Schonewolf, Caitlin A.; McHugh, Jonathon B.; Nyati, Mukesh K.; Eisbruch, Avraham; Mierzwa, Michelle L.
- Abstract
Background: We sought to characterize early changes in CD8+ tumor‐infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16‐positive oropharyngeal cancer on a phase II clinical de‐escalation trial. Methods: Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8+ tumor‐infiltrating lymphocytes and transcriptomes were assessed. Results: One week after cetuximab, five patients (62.5%) had an increase in CD8+ cell infiltration with a median (range) fold change of +5.8 (2.5–15.8). Three (37.5%) had unchanged CD8+ cells (median [range] fold change of −0.85 [0.8–1.1]). In two patients with evaluable RNA, cetuximab induced rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways. Conclusions: Within 1 week, cetuximab induced measurable changes in pro‐cytotoxic T‐cell signaling and immune content.
- Subjects
CETUXIMAB; TUMOR microenvironment; OROPHARYNX; TUMOR-infiltrating immune cells; TYPE I interferons
- Publication
Head & Neck, 2023, Vol 45, Issue 5, p1281
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.27344